Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Gilbert J Burckart

Showing results (71-80 of 129) with videos related to

Pageof 13
Sort By:
Basic & Clinical Pharmacology & Toxicology|April 4, 2012
Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patientsIn-Wha Kim, Hyejin Noh, Eunhee Ji, et al.
Journal of Clinical Pharmacology|September 11, 2019
Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane TransportersKit Wun Kathy Cheung, Bianca D van Groen, Gilbert J Burckart, et al.
Journal of Clinical Pharmacology|January 10, 2025
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in PregnancyXiaomei I Liu, Dionna J Green, John van den Anker, et al.
Clinical Pharmacology and Therapeutics|December 20, 2018
Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug DevelopmentJian Wang, Shaun S Kumar, Catherine M Sherwin, et al.
The AAPS Journal|April 22, 2021
Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral ProductsGopal Pawar, Fang Wu, Liang Zhao, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 21, 2007
Qualification of biomarkers for drug development in organ transplantationGilbert J Burckart, Shashi Amur, Federico M Goodsaid, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 12, 2010
Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patientsErin L Ohmann, Gilbert J Burckart, Maria M Brooks, et al.
Clinical Pharmacology and Therapeutics|February 8, 2020
Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug AdministrationYifei Zhang, Yaning Wang, Mona Khurana, et al.
Journal of Clinical Pharmacology|June 17, 2020
Dosing Recommendations for Pediatric Patients With Renal ImpairmentAmer Al-Khouja, Kyunghun Park, Daijha J C Anderson, et al.
Transplantation|June 18, 2004
P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejectionVera S Donnenberg, Gilbert J Burckart, Adriana Zeevi, et al.
Pageof 13

Showing results (71-80 of 129) with videos related to

Sort By:
Pageof 13
Basic & Clinical Pharmacology & Toxicology|April 4, 2012
Identification of factors affecting tacrolimus level and 5-year clinical outcome in kidney transplant patientsIn-Wha Kim, Hyejin Noh, Eunhee Ji, et al.
Journal of Clinical Pharmacology|September 11, 2019
Incorporating Ontogeny in Physiologically Based Pharmacokinetic Modeling to Improve Pediatric Drug Development: What We Know About Developmental Changes in Membrane TransportersKit Wun Kathy Cheung, Bianca D van Groen, Gilbert J Burckart, et al.
Journal of Clinical Pharmacology|January 10, 2025
Physiologically based Pharmacokinetic/Pharmacodynamic Modeling (PBPK/PD) of Famotidine in PregnancyXiaomei I Liu, Dionna J Green, John van den Anker, et al.
Clinical Pharmacology and Therapeutics|December 20, 2018
Renal Clearance in Newborns and Infants: Predictive Performance of Population-Based Modeling for Drug DevelopmentJian Wang, Shaun S Kumar, Catherine M Sherwin, et al.
The AAPS Journal|April 22, 2021
Development of a Pediatric Relative Bioavailability/Bioequivalence Database and Identification of Putative Risk Factors Associated With Evaluation of Pediatric Oral ProductsGopal Pawar, Fang Wu, Liang Zhao, et al.
American Journal of Transplantation : Official Journal of the American Society of Transplantation and the American Society of Transplant Surgeons|December 21, 2007
Qualification of biomarkers for drug development in organ transplantationGilbert J Burckart, Shashi Amur, Federico M Goodsaid, et al.
The Journal of Heart and Lung Transplantation : the Official Publication of the International Society for Heart Transplantation|January 12, 2010
Genetic polymorphisms influence mycophenolate mofetil-related adverse events in pediatric heart transplant patientsErin L Ohmann, Gilbert J Burckart, Maria M Brooks, et al.
Clinical Pharmacology and Therapeutics|February 8, 2020
Exposure-Response Assessment in Pediatric Drug Development Studies Submitted to the US Food and Drug AdministrationYifei Zhang, Yaning Wang, Mona Khurana, et al.
Journal of Clinical Pharmacology|June 17, 2020
Dosing Recommendations for Pediatric Patients With Renal ImpairmentAmer Al-Khouja, Kyunghun Park, Daijha J C Anderson, et al.
Transplantation|June 18, 2004
P-glycoprotein activity is decreased in CD4+ but not CD8+ lung allograft-infiltrating T cells during acute cellular rejectionVera S Donnenberg, Gilbert J Burckart, Adriana Zeevi, et al.
Pageof 13